News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|May 9, 2024

Potential Novel Schizophrenia Treatments

Author(s)John M. Kane, MD, Erin Crown, MHS, PA-C, Psych-CAQ

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.

Episodes in this series

EP. 1 Burden, Stigma, and Prevalence of Schizophrenia

EP. 1 Burden, Stigma, and Prevalence of Schizophrenia

Video 2 - "Exploration into the Management of the Three Symptom Domains of Schizophrenia"

EP. 2 Exploration into the Management of the Three Symptom Domains of Schizophrenia

Video 3 - "Insights on the Pathophysiology of Schizophrenia"

EP. 3 Insights on the Pathophysiology of Schizophrenia

Video 4 - "Physician Awareness of Cognitive Dysfunction in Schizophrenia"

EP. 4 Physician Awareness of Cognitive Dysfunction in Schizophrenia

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia

EP. 5 Potential Novel Schizophrenia Treatments

Video 6 - "Future Perspectives on Schizophrenia Care"

EP. 6 Future Perspectives on Schizophrenia Care

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Tips for Leveraging Motivational Interviewing in LAI Discussions in Schizophrenia

ByGerald A. Maguire, MD

July 12th 2026

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

ByHeidi Anne Duerr, MPH

July 11th 2026

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

ByGerald A. Maguire, MD

July 11th 2026

Trsakaoe/Adobe Stock

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

ByJessica Walters

July 6th 2026

women's mental health

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

BySusan Hatters Friedman, MD, MSt, DFAPA,Ashley A. Mulvihill, MD

June 25th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

Tips for Leveraging Motivational Interviewing in LAI Discussions in Schizophrenia

Filling the Gap Between IV Ketamine Clinical Use and Evidence-Based Standards